<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00914043</url>
  </required_header>
  <id_info>
    <org_study_id>NSABP B-45.1</org_study_id>
    <secondary_id>NSABP-B-45.1</secondary_id>
    <nct_id>NCT00914043</nct_id>
  </id_info>
  <brief_title>Studying Biological Markers of Fatigue in Women With Residual Invasive Breast Cancer Enrolled on Clinical Trial NSABP-B-45</brief_title>
  <official_title>Biobehavioral Mechanisms of Fatigue in Patients Treated on NSABP B-45: A Phase III Clinical Trial Comparing Adjuvant Sunitinib Malate to Placebo in Women With Residual Invasive Breast Cancer Following Neoadjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NSABP Foundation Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NSABP Foundation Inc</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help&#xD;
      doctors learn more about changes that occur in DNA and identify biomarkers related to&#xD;
      fatigue.&#xD;
&#xD;
      PURPOSE: This research study is looking at biological markers of fatigue in women with&#xD;
      residual invasive breast cancer enrolled on clinical trial NSABP-B-45.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To collect serial blood specimens at each time point that quality of life and&#xD;
           patient-reported outcome assessments are performed in women with residual invasive&#xD;
           breast cancer concurrently enrolled on and participating in the Behavioral and Health&#xD;
           Outcomes component of clinical trial NSABP-B-45.&#xD;
&#xD;
        -  To prepare, separate, and store the blood specimens at the NSABP Serum Bank at Baylor&#xD;
           College of Medicine Breast Center into components for future DNA, RNA, and plasma&#xD;
           analysis.&#xD;
&#xD;
        -  To analyze specific proinflammatory cytokines, genetic polymorphisms, and RNA expression&#xD;
           arrays in collaborating laboratories at University of California, Los Angeles (UCLA).&#xD;
&#xD;
        -  To examine the association between markers of inflammation and symptoms of fatigue among&#xD;
           patients treated with sunitinib malate or placebo on clinical trial NSABP-B-45.&#xD;
&#xD;
        -  To examine the relationship between single-nucleotide polymorphisms in the promoter&#xD;
           regions of IL-1 and IL-6 and symptoms of fatigue in these patients.&#xD;
&#xD;
        -  To examine the relationship between RNA expression profiles and fatigue and compare the&#xD;
           pattern of expression in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients undergo blood sample collection* at baseline and then at 3, 6, 12, 18, and 24 months&#xD;
      for analysis of plasma concentrations of inflammatory biomarkers (IL-1ra, sTNFRII, sIL-6R,&#xD;
      and C-reactive protein) by ELISA; DNA polymorphisms in the promoter regions of IL-6 and IL-1&#xD;
      by TaqMan PCR; and RNA gene expression signaling pathways by RT-PCR assays and microarray.&#xD;
&#xD;
      NOTE: *Blood samples are collected at the same time points that the Behavioral and Health&#xD;
      Outcomes quality of life and patient-reported outcomes questionnaires are completed on&#xD;
      clinical trial NSABP-B-45.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn as NCI rescinded approval for parent study NSABP-B-45&#xD;
  </why_stopped>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Biological and behavioral predictors of fatigue in breast cancer patients at 12 and 24 months after randomization and initiation of treatment on clinical trial NSABP-B-45</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship between specific single-nucleotide polymorphisms in the promoter regions of IL-1 and IL-6 and circulating markers of inflammation and symptoms of fatigue</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship between RNA gene expression pathways and symptoms of fatigue</measure>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Fatigue</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biologic sample preservation procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>enzyme-linked immunosorbent assay</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>fatigue assessment and management</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of residual invasive breast cancer&#xD;
&#xD;
               -  Stage II, IIIA, or IIIB disease&#xD;
&#xD;
               -  HER2/neu-negative disease&#xD;
&#xD;
          -  Randomized to receive either sunitinib malate or placebo on clinical trial NSABP-B-45&#xD;
&#xD;
               -  Has not started therapy on clinical trial NSABP-B-45&#xD;
&#xD;
          -  Has completed baseline Behavioral and Health Outcome questionnaires on clinical trial&#xD;
             NSABP-B-45&#xD;
&#xD;
          -  Hormone-receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman Wolmark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NSABP Foundation Inc</affiliation>
  </overall_official>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>June 3, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2009</study_first_posted>
  <last_update_submitted>January 10, 2013</last_update_submitted>
  <last_update_submitted_qc>January 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fatigue</keyword>
  <keyword>HER2-negative breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

